Blood Metabolomic Predictors of 1-Year Outcome in Subarachnoid Hemorrhage
- 296 Downloads
Delayed neurological deficit (DND) is the most important cause of morbidity and mortality in patients with subarachnoid hemorrhage (SAH) whose aneurysms have been secured. However, the methods currently used to predict the development of DND, such as trans-cranial Doppler or levels biochemical markers in blood and cerebrospinal fluid are not very accurate.
Venous blood was drawn from 50 patients with SAH, admitted to the neurosurgical department Umeå University Hospital, at day 1–3 and day 7 after the bleed. The clinical status of the patients was followed up approximately 1 year after this episode and classified according to the Glasgow Outcome Score (GOS).
Results showed considerable differences in blood metabolomic patterns between day 1–3 and 7 after the hemorrhage. Fifty-six out of 98 metabolites could be identified from our in-house library and 17 of these metabolites changed significantly from day 1–3 to 7 after the bleed. One of these, myo-inositol, was predictive of clinical outcome even after correction for multiple testing. An estimation of the diagnostic accuracy of high levels of this substance in predicting good outcome (GOS 4–5) yielded a sensitivity of .763 and a specificity of .5 at the optimal cut off point.
SAH is an event with a profound effect on blood metabolomics profiles. Myo-inositol might be an interesting compound for future study to focus on in the search for metabolic markers in venous blood of delayed neurological deterioration in SAH patients.
KeywordsDelayed neurological deficit Myo-inositol Metabolomics Subarachnoid hemorrhage Vasospasm Venous blood
This research was supported by Grants from the County Council of Västerbotten, Sweden, and by Umeå University.
Conflict of interest
The authors have no conflicts of interest to declare.
- 6.Dreier J, Ebert N, Priller J, Megow D, Lindauer U, Klee R, Reuter U, Imai Y, Einhäupl KM, Victorov I, Dimagl U. Products of hemolysis in the subarachnoid space inducing spreading ischemia in the cortex and focal necrosis in rats: a model for delayed ischemic neurological deficits after subarachnoid hemorrhage? J Neurosurg. 2000;93:658–66.CrossRefPubMedGoogle Scholar
- 8.Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2011;31(6):1443–51.PubMedCentralCrossRefPubMedGoogle Scholar
- 15.Jung CS, Lange B, Zimmerman M, Zimmerman S. The CSF concentration of ADMA, but not of ET-1, is correlated with the occurrence and severity of cerebral vasospasm after subarachnoid hemorrhage. Neurosci Lett. 2012;22(524):20416.Google Scholar
- 29.Pickard JD, Murray GD, Illingworth R, Shaw MDM, Teasdale GM, Foy PM, Humphrey PRD, Lang DA, Nelson R, Richards P, Sinar J, Bailey S, Skene A. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298:636–42.PubMedCentralCrossRefPubMedGoogle Scholar
- 31.Pluta RM, Hansen-Schwartz J, Dreier J, Vajkoczy P, MacDonald L, Nishizawa S, Kasuva H, Wellman G, Keller E, Zauner A, Dorsch N, Clark J, Ono S, Kiris T, LeRoux P, Zhang JH. Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought. Neurol Res. 2009;31:151–8.PubMedCentralCrossRefPubMedGoogle Scholar